King-friend Shares

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a pharmaceutical group company integrating production, research, and sales. The company entered the heparin sodium industry in 1987 and was listed on the A-share market of the Shanghai Stock Exchange on July 19, 2017, with a market value exceeding 40 billion yuan.

The company has a diversified industrial layout, currently involving APIs, preparations, internet platforms, CDMO, and hotels. It owns several subsidiaries, including Chengdu Jianjin, Hong Kong King-friend, US MH, and operations in Israel.

The company is a major global producer of heparin sodium, with over 30 years of experience in heparin production. Heparin sodium is an anticoagulant and antithrombotic drug for cardiovascular and cerebrovascular diseases. It is a mandatory medication in European and American markets and a basic drug in China's medical insurance, mainly sold to Europe, the United States, Germany, Brazil, Japan, and other regions.

The company's products are primarily filed in both China and the US. Currently, its marketed products cover areas such as anticoagulation and antithrombosis, cardiovascular and cerebrovascular diseases, anti-tumor drugs, anesthetics, and surgical adjuncts. It is one of the few domestic companies that have passed quality certifications from the US FDA, EU EDQM, Japan PMDA, Brazil ANVISA, and the UK MHRA. The company holds honors such as High-tech Enterprise of Jiangsu Province and Postdoctoral Innovation Practice Base of Jiangsu Province.

In terms of preparation marketing, the company deeply strengthens interaction with the internet wave. As a pioneer in the internetization of the pharmaceutical field, it has formed a marketing and support team of over 100 people, including pharmaceutical marketing, academic promotion, and internet software support, with domestic preparation sales growing at a multiple rate each year.

Through thirty years of hard work, the company upholds the pure piety of pharmaceutical professionals, always practicing the mission and responsibility of "driving domestic drug development with international standards, entering the international drug market with international capabilities, and striving for the health and well-being of society and humanity." It remains true to its original aspiration, shoulders responsibility, and continuously works to promote Chinese injectable products to go global and expand in the international market.



【Talent Development Policy】

1. The company will adopt a three-level training approach at the "company level, department level, and position level." New employees are assigned mentors and receive "one-on-one" work guidance, using the "JI decomposition" training method to ensure they quickly integrate into the company.

2. The company has a complete dual-channel career development system: the management channel and the technical channel. The company organizes promotion applications quarterly, evaluating personnel through both management and technical aspects.

3. The company has a comprehensive training system, organizing regular annual training at the company and department levels, conducting ad-hoc job training (including special topics, documents, management, and other categories), and also arranging external training based on different job needs.



【Welfare and Incentive Policies】

1. Regular welfare: five social insurances and one housing fund, supplementary medical insurance for children, annual physical examination, holiday benefits, paid leave, shuttle bus, working meals, and accommodation for non-local staff.

2. Incentive benefits: performance-based salary, year-end bonus, equity incentives, and two salary adjustments per year.

Working hours:

Non-production positions: five days on and two days off, 8:15-17:00.

Production positions: four days on and two days off (specific working hours are based on production plans).